Stay updated on Pembrolizumab in Recurrent HNSCC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Recurrent HNSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Recurrent HNSCC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The Phase II pembrolizumab trial record is displayed with its study design, eligibility criteria, locations, and outcome measures, replacing an error page.
    Difference
    48%
    Check dated 2026-11-07T13:07:26.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0 while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T13:50:13.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A sitewide notice announces that NIH is transitioning to the term “Super Intelligence” in place of “Artificial Intelligence” and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T13:18:41.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer’s site revision label changed from v3.7.1 to v3.7.2 on the 403 Forbidden page, while the study record remains unavailable.
    Difference
    0.2%
    Check dated 2026-10-17T14:19:25.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T14:15:01.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The study page now returns a 403 Forbidden error, replacing the previous study record content with a standard site header, navigation, and footer. This indicates the record is not accessible at this time.
    Difference
    17%
    Check dated 2026-09-19T20:28:39.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Recurrent HNSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent HNSCC Clinical Trial page.